Shire will cut UK R&D to focus on rare diseases


Shire Pharmaceutcals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. The move is part of an ongoing restructuring plan that will see the company focus on treatments for rare diseases.

The Basingstoke site employs around 170 researchers, but many of the research programmes they are engaged in fall outside of Shire’s new target areas, and will be halted. The company has not yet confirmed how many will lose their jobs. The site will continue to provide corporate and support functions in the UK.

Meanwhile, Shire has agreed to pay $4.2 billion (£2.6 billion) for rare disease specialists ViroPharma. The deal brings Shire a clutch of drugs, including Cinryze (C1 esterase inhibitor [human]) for prophylactic treatment of hereditary angioedema (HAE). Shire’s own HAE drug, Firazyr (icatibant), can be used to treat acute attacks of the disease, so the two treatments are complementary.

The deal also includes treatments for adrenal insufficiency and seizures in children and infants, as well as several candidates in Phase II clinical trials.


Related Content

Shire fends off AbbVie takeover bid

23 June 2014 Business

news image

Board says deal undervalues the company and its growth potential

Orphans come in from the cold

30 August 2011 Premium contentFeature

news image

Rare diseases are less rare than you might think, reports Bea Perks, and finding drugs for them can mean big business

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Spanish fly

10 October 2013 Podcast | Compounds

news image

Helen Scales looks at cantharidin, the active ingredient in this famous aphrodisiac

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company